JGP Wealth Management LLC Has $13.73 Million Holdings in Johnson & Johnson (NYSE:JNJ)

JGP Wealth Management LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 14.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 77,741 shares of the company’s stock after purchasing an additional 9,660 shares during the quarter. Johnson & Johnson accounts for 2.5% of JGP Wealth Management LLC’s holdings, making the stock its 7th biggest position. JGP Wealth Management LLC’s holdings in Johnson & Johnson were worth $13,733,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of JNJ. Veracity Capital LLC increased its position in shares of Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after purchasing an additional 59 shares during the period. Sandy Cove Advisors LLC grew its position in Johnson & Johnson by 1.6% in the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after acquiring an additional 60 shares during the last quarter. LCM Capital Management Inc grew its position in Johnson & Johnson by 0.7% in the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after acquiring an additional 61 shares during the last quarter. Arbor Investment Advisors LLC grew its position in Johnson & Johnson by 2.3% in the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after acquiring an additional 61 shares during the last quarter. Finally, Sierra Capital LLC grew its position in Johnson & Johnson by 0.6% in the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after acquiring an additional 61 shares during the last quarter. 67.94% of the stock is owned by institutional investors.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on JNJ shares. Atlantic Securities decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. UBS Group started coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Morgan Stanley lifted their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. Finally, Guggenheim started coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Price Performance

Shares of JNJ opened at $158.91 on Monday. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The business’s 50 day moving average price is $159.70 and its two-hundred day moving average price is $166.20. The firm has a market cap of $412.96 billion, a PE ratio of 33.24, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.67 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s payout ratio is currently 94.56%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.